The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progression
These findings suggest that the mGPS measured at the time of radiologic PD can identify patients with a better prognosis who may benefit from continued atezolizumab therapy, aiding in the selection for TBP in clinical practice.
Authors
- Viktor Grünwald (ORCID: https://orcid.org/0000-0003-2083-7687)
- Michael Hölzel (ORCID: https://orcid.org/0000-0003-4048-8824)
- Manuel Ritter (ORCID: https://orcid.org/0000-0001-8667-2067)
- Jonas Saal (ORCID: https://orcid.org/0000-0002-9647-2947)
- Peter Brossart
- Niklas Klümper (ORCID: https://orcid.org/0000-0002-3258-0586)
- Markus Eckstein (ORCID: https://orcid.org/0000-0001-5418-3349)
Institutions
- University Hospital Bonn (DE)
- Düsseldorf University Hospital (DE)
- Integrated Oncology (United States) (US)
- Essen University Hospital (DE)
- Comprehensive Cancer Center Erlangen (DE)
- Heinrich Heine University Düsseldorf (DE)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1016/j.ejca.2024.115163
- Citations
- 10
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.83
Funders
- Deutsche Krebshilfe
- Rheinische Friedrich-Wilhelms-Universität Bonn
- Medizinische Fakultät, Rheinische Friedrich-Wilhelms-Universität Bonn